Summary
Endothelia in the atrioventricular (AV) canal of the developing heart undergo a prototypical epithelial mesenchymal transition (EMT) to begin heart valve formation. Using an in vitro invasion assay, an extracellular matrix protein, Olfactomedin-1 (OLFM1), was found to increase mesenchymal cell numbers in AV canals from embryonic chick hearts. Treatment with both anti-OLFM1 antibody and siRNA targeting OLFM1 inhibits mesenchymal cell formation. OLFM1 does not alter cell proliferation, migration or apoptosis. Dispersion, but lack of invasion in the presence of inhibiting antibody, identifies a specific role for OLFM1 in cell invasion during EMT. This role is conserved in other epithelia, as OLFM1 similarly enhances invasion by MDCK epithelial cells in a transwell assay. Synergy is observed when TGFβ2 and OLFM1 are added to MDCK cell cultures, indicating that OLFM-1 activity is cooperative with TGFβ. Inhibition of both OLFM1 and TGFβ in heart invasion assays shows a similar cooperative role during development. To explore OLFM1 activity during EMT, representative EMT markers were examined. Effects of OLFM1 protein and anti-OLFM1 on transcripts of cell-cell adhesion molecules and the transcription factors Snail-1, Snail-2, Twist1 and Sox-9 argue that OLFM1 does not initiate EMT. Rather, regulation of transcripts of Zeb1 and Zeb2, secreted proteases and mesenchymal cell markers by both OLFM1 and anti-OLFM1 is consistent with regulation of the cell invasion step of EMT. We conclude that OLFM1 is present and necessary during EMT in the embryonic chick heart. Its role in cell invasion and mesenchymal cell gene regulation suggests an invasion checkpoint in EMT where OLFM1 acts to promote cell invasion into the three-dimensional matrix.
- Received July 20, 2012.
- Accepted December 12, 2012.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
Editor's Choice – Lifespan analysis of phenotypes in three mouse models of Down syndrome
A comparison of three mouse models of Down syndrome by Diana W. Bianchi and co-workers reveals widespread and unexpected fundamental differences in behavioural, gene expression and brain development phenotypes.
Find out more about the story behind this Editor's Choice article in an interview with first author Nadine M. Aziz.
Review – Hidden features: exploring the non-canonical functions of metabolic enzymes
A new Review from Peiwei Huangyang and M. Celeste Simon, part of our upcoming special issue on Cancer metabolism, summarizes recent findings about multifaceted metabolic enzymes with non-canonical activities outside their core biochemical functions, and how they may provide new therapeutic strategies for cancers.
Featured article – Intramyocardial angiogenetic stem cells and epicardial erythropoietin save the acute ischemic heart
Gustav Steinhoff and colleagues report that cardiac mesenchymal stem cells respond early to myocardial infarction, and that their regenerative capacity is directly upregulated by optimized stimulation of the heart through epicardial erythropoietin delivery.
First Person interviews
Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Nadine Aziz, Tingting Sui, Brian Lu, Hannah Gordon, Theresa Kisko, Francisco Javier García-Rodríguez and Laura Schultz.
Why should you publish your next paper in DMM?
DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.
preLights – Using zebrafish to model the effects of candidate disease gene variants in complex human genetic disorders
Highlighted by Hannah Brunsdon, a recent preprint from Lisa Maves and co-workers describes the first example of modelling a complex genetic disorder in zebrafish, and demonstrates that a human candidate disease variant of unknown significance acts as a modifier gene for congenital heart defects.